Particle.news
Download on the App Store

Oddity Launches Methodiq, an AI-Powered Teledermatology Platform in the U.S.

The company targets medical skincare demand by applying proprietary imaging plus biotech to its 60 million‑user base.

Overview

  • Methodiq debuts with 28 products and more than 100 personalized plans spanning prescription, over‑the‑counter and cosmetic options for acne, hyperpigmentation and eczema.
  • Patients complete a selfie and questionnaire that feed an AI profile for clinician review, followed by weekly app check‑ins with computer vision tracking and in‑app chat support rather than video visits.
  • Formulations draw on Oddity Labs’ biotech, with examples including Clindalaq 305, Trazelaq 305, oral spironolactone, and an acne‑scar treatment using molecule ODDL103, plus acne‑safe foundation and concealer.
  • Oddity says every intake is reviewed by a U.S.-based medical doctor, not all of whom are board‑certified dermatologists, and the platform does not accept insurance.
  • Positioned against incumbents like Hims, the launch includes an out‑of‑home campaign with New York City subway ads, with products priced roughly $29 to $59 and near‑term revenue impact described as limited.